Nathalie Pelletier-Fleury

Nathalie Pelletier-Fleury

Auto-generated profile, based on publicly available information

Nathalie Pelletier-Fleury

Center for Research in Epidemiology and Population Health, Inserm Unité Mixte de Recherche (UMR) 1018, Paris Saclay University, Versailles Saint Quentin University, Villejuif, France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2001 in Sleep Medicine
Verified
Journal Article
Closed access
NPNathalie Pelletier-Fleury
Nathalie Pelletier-Fleury
DRDominique Rakotonanahary
Dominique Rakotonanahary
BFBernard Fleury
Bernard Fleury

1 January 2016 in Chest
Verified
Journal Article
Closed access
FGFrederic Gagnadoux
Frederic Gagnadoux
MVMarc Le Vaillant
Marc Le Vaillant
APAudrey Paris
Audrey Paris
TPThierry Pigeanne
Thierry Pigeanne
LLLaurence Leclair-Visonneau
Laurence Leclair-Visonneau
NPNathalie Pelletier-Fleury
Nathalie Pelletier-Fleury

1 February 2006 in SLEEP
Verified
Journal Article
Open access
PDF file
VGVirginie Godet-Cayré
Virginie Godet-Cayré
NPNathalie Pelletier-Fleury
Nathalie Pelletier-Fleury
MVMarc Le Vaillant
Marc Le Vaillant
JDJérôme Dinet
Jérôme Dinet
MMMarie-Anne Massuel
Marie-Anne Massuel
DLDamien Léger
Damien Léger
To estimate the costs of insomnia-associated work absenteeism and to analyze how these costs are shared between the different payers: the national health insurance system, employers, and employees. Retrospective cohort study over a 2-year period. The Paris Ile de France region. Two matched groups of employees: 369 insomniacs and 369 good sleepers. The costs of absenteeism at work associated with insomnia were estimated by comparing the 2 matched groups in terms of the number and duration of work absences. We considered that work absences incurred costs relating to salary replacement and loss of productivity: these were given a monetary value on the basis of the added value per hour worked. The percentage of employees with at least 1 work absence are 50% and 34% for insomniacs and good sleepers, respectively. The work absenteeism (expressed in days, per employee, per year ± confidence intervals [CI]) differed significantly between insomniacs and good sleepers: 5.8 (± 1.1 ) and 2.4 (± 0.5), respectively (p < .001). The extra cost (± CI) to the national health insurance system of insomnia-associated absenteeism was estimated at € 77 (±€ 39) per employee, per year. The extra cost (± CI) to employers was estimated at € 233 (±€ 101) for salary replacement and € 1062 (±€ 386) for loss of productivity. Finally, employees themselves bore a cost (± CI) of € 100 (±€ 54). Employees who suffered from insomnia had a significantly higher rate of absenteeism at work than those who slept well. This absence represents a cost for society: in France, 88% of this amount is shouldered by employers.

1 May 2004 in Chest
Verified
Journal Article
Closed access
BFBernard Fleury
Bernard Fleury
DRDominique Rakotonanahary
Dominique Rakotonanahary
BPBoris Petelle
Boris Petelle
GVGérard Vincent
Gérard Vincent
NFNathalie Pelletier Fleury
Nathalie Pelletier Fleury
BLBernard Lebeau
Bernard Lebeau

1 January 2003 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
NPN. Pelletier-Fleury
N. Pelletier-Fleury
NMN. Meslier
N. Meslier
FGFrederic Gagnadoux
Frederic Gagnadoux
CPC. Person
C. Person
DRD. Rakotonanahary
D. Rakotonanahary
JRJ-L. Racineux
J-L. Racineux
The objective of this study was to measure the impact of a 6‐month delay in the diagnosis and treatment of patients with moderate obstructive sleep apnoea syndrome (OSAS) (apnoea/hypopnoea index (AHI) <30) or severe OSAS (AHI ≥30) on daytime sleepiness, cognitive functions, quality of life and healthcare expenditure (hospitalisations, medical visits, complementary tests, biological tests and drug prescriptions). In addition, this study aimed to analyse the incremental cost effectiveness ratios related to daytime sleepiness or quality of life following immediate introduction of treatment in these two populations.This study was conducted as a multicentre randomised controlled trial and carried out at two teaching hospitals in France. A total of 171 patients were followed for 6 months, with 82 patients randomised to group 1 “immediate polysomnography” and 89 in group 2 “polysomnography within 6 months”.Patients with severe OSAS were deprived of a significant improvement of their daytime sleepiness (5.1±5.0 at the Epworth Sleepiness Scale score in group 1versus0.2±3.4 in group 2) and quality of life (12.4±13.3 at the Nottingham Health Profile score in group 1versus0.7±10.1 in group 2) during the waiting time. The impact of delayed management in subjects with less severe OSAS only concerned daytime sleepiness (1.9±3.3 in group 1versus0.3±4.3 in group 2). Delayed treatment did not affect cognitive functions or healthcare expenditure regardless of the severity of the disease. Incremental cost effectiveness ratios related to rapid introduction of treatment were significantly lower in the patients with more severe OSAS.These results provide fairly clear medical and economic arguments in favour of early management of patients with more severe forms of obstructive sleep apnoea syndrome.

1 February 2001 in Chest
Verified
Journal Article
Closed access
DRDominique Rakotonanahary
Dominique Rakotonanahary
NPNathalie Pelletier-Fleury
Nathalie Pelletier-Fleury
FGFrédéric Gagnadoux
Frédéric Gagnadoux
BFBernard Fleury
Bernard Fleury